Advertisement

Multiple Myeloma and Plasmacytoma

  • Mohamad Hussein
Part of the Current Clinical Oncology book series (CCO)

Abstract

Multiple myeloma (MM) is a clonal disorder of B-cell lymphocytic lineage characterized by malignant transformation of plasma cells. It accounts for approx 10% of all the hematological malignancies and 1% of all cancers in the United States. In the year 2000, MM was diagnosed in approx 13,700 people in the United States and accounted for 20% of deaths from hematological malignancies (1). The median age of onset is 68 yr. It is slightly more frequent in women and the incidence in African-Americans is twice that of Whites. Both the overall incidence and specifically the incidence in African-Americans have been rising in recent years. A recent study explored whether dietary factors contribute to the risk of MM and the twofold higher incidence among Blacks compared with Whites in the United States. Data from a food frequency questionnaire were analyzed for 346 White and 193 Black subjects with MM, and 1086 White and 903 Black controls who participated in a population-based case-control study of MM in three areas of the United States. This study concluded that the greater use of vitamin C supplements by Whites and the higher frequency of obesity among Blacks may explain part of the higher incidence of MM among Blacks compared to Whites in the United States.

Keywords

Multiple Myeloma Clin Oncol Bone Marrow Stromal Cell Monoclonal Protein Poem Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 1999; 49:8–31.PubMedCrossRefGoogle Scholar
  2. 2.
    Brown LM, Gridley G, Pottern LM, et al. Diet and nutrition as risk factors for multiple myeloma among blacks and whites in the United States. Cancer Causes Control 2001; 12:117–125.PubMedCrossRefGoogle Scholar
  3. 3.
    Anderson KC, Lust JA. Role of cytokines in multiple myeloma. Semin Hematol 1999; 36:14–20.PubMedGoogle Scholar
  4. 4.
    Grigorieva I, Thomas X, Epstein J. The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone. Exp Hematol 1998; 26:597–603.PubMedGoogle Scholar
  5. 5.
    Bataille R, Barlogie B, Lu ZY, et al. Biologic effects of anti-IL-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995; 86:685–691.PubMedGoogle Scholar
  6. 6.
    Podar K, Tai Y, Davies FE, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001; 98:428–435.PubMedCrossRefGoogle Scholar
  7. 7.
    Roodman GD. Biology of osteoclast activation in cancer. J Clin Oncol 2001; 19:3562–3571.PubMedGoogle Scholar
  8. 8.
    Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clinic Proc 1975; 50:29–40.Google Scholar
  9. 9.
    Dammacco F, Castoldi G, Rodjer S. Efficacy of epoetin alfa in the treatment of anemia of multiple myeloma. Br J Haematol 2001; 113:172–179.PubMedCrossRefGoogle Scholar
  10. 10.
    William JW, Beutler E, Ersler AJ, Roudles RW. Hematologia. 1st ed. 1975:968–1002.Google Scholar
  11. 11.
    Gomez AR, Harley JB. Multiple myeloma and pernicious anemia. W V Med J 1970; 66:38–41.PubMedGoogle Scholar
  12. 12.
    Miramon Lopez J., Ruiz Cantero A., Morales Jimenez J., Lara Fernandez A., Hita Perez J. [A new case of association of multiple myeloma and megaloblastic anemia.] An Med Interna 1999; 16:654–655.PubMedGoogle Scholar
  13. 13.
    Gharton G, Tura S, Svensson H, et al. Allogeneic bone marrow transplantation in multiple myeloma: an update of the EBMT registry. Boston, MA: Harvard Medical School. Sixth International Workshop on Multiple Myeloma. Syllabus, Boston, MA, 1997, June 14–18.Google Scholar
  14. 14.
    Blade J, San Miguel JF, Fontanillas M, et al. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intesification/autotransplantation and who were conventionally treated. J Clin Oncol 1996; 14:2167–2173PubMedGoogle Scholar
  15. 15.
    Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93:55–65.PubMedGoogle Scholar
  16. 16.
    Attal M, Harousseau JL, Facon T, et al. Single versus double transplant in myeloma: a randomized trial of the “Inter Groupe Francais Du Myélome” (IFM). Blood 1999; 94:714a.Google Scholar
  17. 17.
    Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy Blood 2000; 96:2943–2950.Google Scholar
  18. 18.
    Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20:4319–4323.PubMedCrossRefGoogle Scholar
  19. 19.
    Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21:16–19.PubMedCrossRefGoogle Scholar
  20. 20.
    Bladé J, López-Guillermo A, Bosch F, et al. Impact of response to treatment on survival in multiple myeloma: Results in a series of 243 patients. Br J Haematol 1994; 88:117–121.PubMedCrossRefGoogle Scholar
  21. 21.
    Myeloma Trialists’ Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 2001; 113:1020–1034.CrossRefGoogle Scholar
  22. 22.
    Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984; 310:1353–1356.PubMedGoogle Scholar
  23. 23.
    Rogers MJ, Watts DJ, Russell RG. Overview of bisphosphonates. Cancer 1997; 80:1652–1660.PubMedCrossRefGoogle Scholar
  24. 24.
    Yoneda T, Michigami T, Yi B, et al. Use of bisphosphonates for the treatment of bone metastasis in experimental animal models. Cancer Treat Rev 1999; 25:293–299.PubMedCrossRefGoogle Scholar
  25. 25.
    Terpos E, Palmermos J, Tsionos K, et al. Effect of palmidronate administration on markers of bone turnover and disease activity in multiple myeloma. Eur J Haematol 2000; 65:331–336.PubMedCrossRefGoogle Scholar
  26. 26.
    Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events: Myeloma Aredia Study Group. J Clin Oncol 1998; 16:593–602.PubMedGoogle Scholar
  27. 27.
    Major P, Lortholary A, Hon, J et al. Zolendronic acid is superior to palmidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized controlled clinical trials. J Clin Oncol 2001; 19:558–567.PubMedGoogle Scholar
  28. 28.
    Janjan NA. Radiation for bone metastases: conventional techniques and the role of systemic radiopharmaceuticals. Cancer 1997; 80:1628–1645.PubMedCrossRefGoogle Scholar
  29. 29.
    Dudeney S, Hussein M, Karam MA, et al. Kyphoplasty in the treatment of vertebral compression fractures due to multiple myeloma. 8th Inernational Myeloma Workshop, Banff, Canada 2001, May 4–8: Abstract P156.Google Scholar

Copyright information

© Humana Press, Inc., Totowa, NJ 2006

Authors and Affiliations

  • Mohamad Hussein
    • 1
  1. 1.Taussig Cancer CenterThe Cleveland Clinic FoundationCleveland

Personalised recommendations